Crispr therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Crispr therapeutics Contact Number

Contact. US Office. CRISPR Therapeutics 610 Main Street (enter on Portland Street) Cambridge, MA 02139 617-315-4600. View Map. Switzerland Office. CRISPR Therapeutics Baarerstrasse 14 ZUG V8 CH-6300 Switzerland CH +41 (0)41 561 32 …

Contact US: http://www.crisprtx.com/about-us/contact

Media

33 People Used

See More ››

Contact IR CRISPR Therapeutics

Media Inquiries. Jennifer Paganelli. WCG for CRISPR. 347.658.8290. [email protected]

View Contact ››

CRISPR

27 People Used

See More ››

Home Page CRISPR

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress. May 06, 2021. CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer. Apr

View Contact ››

CRISPR/Cas9

63 People Used

See More ››

CRISPR Therapeutics

Phone Number 141794589327 CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA.

View Contact ››

Crispr

122 People Used

See More ››

Crispr Therapeutics, Inc. Company Profile Cambridge, MA

Crispr Therapeutics, Inc. is located in Cambridge, MA, United States and is part of the Medical & Diagnostic Laboratories Industry. Crispr Therapeutics, Inc. has 5 total employees across all of its locations and generates $719,000 in sales (USD). There are 4 companies in the Crispr Therapeutics, Inc. corporate family.

View Contact ››

CRISPR

117 People Used

See More ››

CRISPR/Cas9 Gene Editing Therapy

CRISPR Therapeutics Investor Contact: Susan Kim, +1 617-307-7503 [email protected] CRISPR Therapeutics Media Contact: Rachel Eides WCG on behalf of CRISPR +1 617-337-4167 [email protected] Vertex Pharmaceuticals Incorporated Investors: Michael Partridge, +1 617-341-6108 or Zach Barber, +1 617-341-6470 or Brenda Eustace, +1 617 …

View Contact ››

CRISPR

121 People Used

See More ››

Vertex Pharmaceuticals and CRISPR Therapeutics Amend

CRISPR Therapeutics Investor Contact: Susan Kim, +1 617-307-7503 [email protected] CRISPR Therapeutics Media Contact: Rachel Eides Real Chemistry on behalf of CRISPR +1 617-337-4167 [email protected]

View Contact ››

CRISPR

44 People Used

See More ››

CRISPR Therapeutics Company Profile

CRISPR Therapeutics has 410 employees across 4 locations and $719 K in annual revenue in FY 2020. See insights on CRISPR Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

View Contact ››

Technology

65 People Used

See More ››

CRISPR Therapeutics, Inc.

CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases.

View Contact ››

Gene-editing

62 People Used

See More ››

CRISPR Therapeutics LinkedIn

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary

View Contact ››

CRISPR

89 People Used

See More ››

CRISPR Therapeutics

CRISPR Therapeutics has raised a total of $127M in funding over 5 rounds. Their latest funding was raised on Dec 14, 2020 from a Grant round. CRISPR Therapeutics is registered under the ticker NASDAQ:CRSP . Their stock opened with $15.00 in its Oct 19, 2016 IPO. CRISPR Therapeutics is funded by 12 investors.

View Contact ››

CRISPR

126 People Used

See More ››

Vertex and CRISPR Therapeutics to Present New Clinical

This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, as well as statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) the safety, efficacy and clinical progress of CRISPR Therapeutics

View Contact ››

Please leave your comments here:

Popular Brands

Cnooc
Cae
Cerner
Crh
Csi